Current and future perspectives in advanced bladder cancer: Is there a new standard?

Seminars in Oncology

Volumn 29, Issue 1 SUPPL. 3, 2002, Pages 3-14

  Von Der Maase, Hans ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; TAXANE DERIVATIVE; VINBLASTINE;

BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DRUG RESPONSE; HUMAN; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS; STANDARD; SURVIVAL RATE; TOXICITY; UROGENITAL TRACT TUMOR;

EID: 0036125838     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.30750     Document Type: Conference Paper

References (67)

1. Chemotherapy for advanced bladder cancer
2. Cisplatin, methotrexate, and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study
3. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for transitional cell carcinoma of the urothelium
4. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse
5. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: Results and a report on prognostic factors in a Medical Research Council study
6. NCCN urothelial cancer practice guidelines
7. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy
8. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma
9. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience
10. Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: Cause for concern
11. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer
12. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder
13. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
14. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors
15. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
16. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial carcinoma
17. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma
18. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: Results of a randomized trial
19. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924
20. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter
21. Paclitaxel in advanced urothelial carcinoma: Its role in patients with renal insufficiency and as salvage therapy
22. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group
23. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma
24. Docetaxel (Taxotere): An active agent in metastatic urothelial cancer: Results of a phase II study in non-chemotherapy-pretreated patients
25. Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel
26. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: An Eastern Cooperative Oncology Group study
27. Phase II study of paclitaxel and cisplatin for advanced urothelial cancer
28. Phase II trial of paclitaxel and cisplatin for metastatic or locally unresectable urothelial cancer
29. Docetaxel and cisplatin in metastatic urothelial cancer: A phase II study
30. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group
31. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: An active and tolerable outpatient regimen
32. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma
33. Paclitaxel and carboplatin in patients with metastatic urothelial cancer: Results of a phase II trial
34. Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: The importance of survival as a clinical trial end point
35. Phase II trial of paclitaxel (P) plus carboplatin (C) in advanced urothelial tract cancer (UTC)
36. Phase II study of Taxol (paclitaxel) and carboplatin in patients with advanced transitional-cell carcinoma of the urothelium: Preliminary results
37. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study
38. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma
39. Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study
40. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum
41. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer
42. Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer
43. Single agent 2′,2′-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: A phase II study
44. Interaction between cisplatin and gemcitabine in vitro and in vivo
45. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial
46. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer
47. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group
48. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: A phase II multicenter trial
49. Gemcitabine and cisplatinum in a 21-day schedule in the first-line treatment of locally advanced or metastatic transitional cell carcinoma: Preliminary results of a phase II study
50. Palliative chemotherapy with gemcitabine (Gem) and carboplatin (CBDCA) in advanced transitional cell carcinoma of the urothelium (ATCCU). Preliminary results
51. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function
52. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study
53. Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract
54. Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy
55. Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer
56. Metastatic urothelial cancer: Evaluation of prognostic factors and change in prognosis during the last twenty years
57. Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors
58. A new regimen of gemcitabine and paclitaxel in previously treated patients with advanced transitional cell carcinoma
59. Paclitaxel and gemcitabine chemotherapy for advanced transitional cell carcinoma of the urothelial tract: A phase II trial of the Minnie Pearl Research Network
60. Gemcitabine (G) and paclitaxel (P) every two weeks (GP2W): A multicenter phase II trial in locally advanced or metastatic urothelial cancer (UC)
61. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer
62. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium
63. The role of ifosfamide in the treatment of testicular and urothelial malignancies
64. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma
65. A phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium
66. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: A phase II trial
67. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: Final report of a phase II trial evaluating two dosing schedules